Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

 
• By Joseph Haas

Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.

Render illustration of Clinical Trial title on medical documents

More from Clinical Trials

More from R&D